Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

NCT02041715 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Ebola Virus Infection

Interventions

DRUG: TKM-100802 for Injection
DRUG: Placebo

Sponsor

Arbutus Biopharma Corporation

Collaborators

[object Object]